Expression of interleukin-6 is downregulated by 17-(allylamino)-17- demethoxygeldanamycin in human prostatic carcinoma cells

Acta Pharmacologica Sinica

Volumn 29, Issue 11, 2008, Pages 1334-1341

  Tsui, Ke Hung ^a   Feng, Tsui Hsia ^b   Hsieh, Wen Chi ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

17 (allylamino) 17 demethoxygeldanamycin; Heat shock protein 90; Interleukin 6; Phorbol 12 myristate 13 acetate; Promoter; Prostate; Prostatic carcinoma cells

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; TANESPIMYCIN;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DOWN-REGULATION; GENETIC VECTORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-6; LACTAMS, MACROCYCLIC; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 55149096184     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00887.x     Document Type: Article

References (27)

1. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, De Miguel MR Immunohistochemical analysis of the IL-6 family of cytokines and their receptor in benign, hyperplasic and malignant human prostate. J Pathol 2004 202 : 41 9.
2. Palmer J, Hertzog PJ, Hammacher A. Differential expression and effects of gpl30 cytokines and receptors in prostate cancer cells. Int J Biochem Cell Biol 2004 36 : 2258 69.
3. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005 95 : 1327 35.
4. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003 97 : 1211 6.
5. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005 11 : 1815 20.
6. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res 2004 64 : 2619 26.
7. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cells growth. J Cell Biochem 2005 95 : 497 505.
8. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996 1 : 97 8.
9. Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemo-therapeutic target. Semin Oncol 2006 33 : 457 65.
10. Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol 2006 3 : 590 600.
11. Solit DB, Scher H, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003 30 : 709 16.
12. Ripley BJM, Isenberg DA, Latchman DS. Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90. J Autoimmun 2001 17 : 341 6.
13. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006 26 : 3409 16.
14. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH. Triiodothyro-nine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 2008 68 : 610 9.
15. Tsui KH, Chang PL, Juang HH. Manganese antagonizes iron blocking mitochondrial acontiase expresson in human prostate carcinoma cells. Asian JAndrol 2006 8 : 307 16.
16. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003 162 : 655 63.
17. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005 11 : 1815 20.
18. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007 67 : 6854 62.
19. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999 38 : 199 207.
20. Abdul M, Hoosein N. Differences in the expression and effects of interleukin-1 and 2 on androgen-sensitive and -insensitive human prostate cancer cell lines. Cancer Let 2000 149 : 37 42.
21. Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, et al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO326. Prostate 2006 66 : 1744 52.
22. Harashima K, Akimoto T, Nonaka T, Tsuzuki K, Mitsuhashi N, Nakano T. Heat shock protein (90) chaperon complex inhibitor radiciol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of androgen receptor. Int J Radiat Biol 2005 81 : 63 76.
23. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003 14 : 1169 76.
24. Wax S, Piecyk M, Maritim B, Anderson P. Geldanamycin inhibits the production of inflammatory cytokines inactivated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum 2003 48 : 541 50.
25. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar W. Cooperative function between nuclear factors NF-κB and CCAAT/enhancer-binding protein-β (C/EBP-β) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004 61 : 354 70.
26. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor κB p50/65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003 63 : 2206 15.
27. Keller ET, Chang C, Ershler WB. Inhibiton of NF-κB activity through maintenance of IκBα levels contributes to dihydrotestosterone- mediated repression of the interleukin-6 promoter. J Biol Chem 1996 271 : 26267 75.